IMC Immuron

Immuron CEO, Steven Lydeamore, to host an investor webinar

Immuron CEO, Steven Lydeamore, to host an investor webinar

MELBOURNE, Australia, Aug. 29, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform for prevention and treatment of gut-mediated diseases; invites investors to join a live webcast hosted by Steven Lydeamore, CEO of Immuron Limited.

Wednesday, 7 September 2022 at 9.00am Australian Eastern Standard Time (AEST).



Register in advance for this webinar:







After registering, you will receive a confirmation email containing information about joining the webinar.

This release has been authorised by the directors of Immuron Limited.

COMPANY CONTACT:



Steven Lydeamore

Chief Executive Officer

Ph: +61 (0)3 9824 5254

  

About Immuron

Immuron Limited (ASX: IMC, NASDAQ: IMRN) is a commercial and clinical-stage Australian biopharmaceutical company with a proprietary technology platform focused on a novel class of orally delivered polyclonal antibodies produced from hyperimmune antibody-rich bovine colostrum, for prevention and treatment of gut-mediated diseases.



For more information visit:

 



EN
29/08/2022

Underlying

IMCImmuron

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Immuron

 PRESS RELEASE
Free
IMC IMMURON

Immuron Reports Continued Sales Growth

Immuron Reports Continued Sales Growth Sales Highlights (unaudited): Global H1 sales AUD$4.2 million up 5% on prior comparative period (pcp)Q2 sales AUD$2.2 million up 11% on prior quarter Australia H1 sales AUD$3.3 million up 13% on prior comparative period (pcp)Q2 sales AUD$1.7 million up 11% on prior quarterAustralian launch of ProIBS® Canada H1 sales AUD$56 thousand down 85% on prior comparative period (pcp)Q2 sales AUD$42 thousand up 191% on prior quarter USA H1 sales AUD$0.9 million up 17% on prior comparative period (pcp)Q2 sales AUD$0.4 million up 8% on prior quarter ...

January 19, 2026 1 EN
 PRESS RELEASE
Free
IMC IMMURON

Immuron New U.S. Department of Defense Award & Clinical Trial Update

Immuron New U.S. Department of Defense Award & Clinical Trial Update Highlights: New US Department of Defense award to develop two new oral therapeutics targeting Campylobacter and ShigellaUniformed Services University P2TD clinical study update MELBOURNE, Australia, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, announces a new research agreement with the Naval Medical Research Command (NMRC) and the Walter Reed Army Institute of Research (WRAIR), Silver Spring, MD, USA funded by a U.S....

December 3, 2025 1 EN
 PRESS RELEASE
Free
IMC IMMURON

Immuron IMM-529 IND approved by FDA

Immuron IMM-529 IND approved by FDA Key Points Immuron receives U.S. Food and Drug administration (FDA) approval for IMM-529 Investigational New Drug (IND) application and clinical study may proceedFDA assigned an IND number (032095) for the IMM-529 application IND 32095 is Immuron’s Investigational new drug (IND) application for clinical development of IMM-529 as product to specifically prevent or treat Clostridioides difficile infection (CDI) and is now active MELBOURNE, Australia, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), is pleased to announce that ...

November 5, 2025 1 EN
 PRESS RELEASE
Free
IMC IMMURON

Immuron Announces Clinical Trial Update

Immuron Announces Clinical Trial Update IMM-529 IND: currently under review, FDA request for Information – minor updates to clinical protocol completed and submitted Travelan® P2TD (n=851) Uniformed Services University study topline data delayed to the end of November due to U.S government shutdown MELBOURNE, Australia, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company provides a clinical trial update on Travelan® and IMM-529. IMM-529 IND (Clostridioides difficile infection)Immuron announced ...

October 31, 2025 1 EN
 PRESS RELEASE
Free
IMC IMMURON

Immuron Q1 FY26 YoY growth

Immuron Q1 FY26 YoY growth Sales Highlights (unaudited): Global•Q1 sales AUD$2.0 million up 34% on prior comparative period (pcp)   Australia•Q1 sales AUD$1.6 million up 52% on pcp   Canada•Q1 sales AUD$0.0 million down 92% on pcp   USA•Q1 sales AUD$0.4 million up 44% on pcp MELBOURNE, Australia, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce continued sales growth (unaudited) of Travelan®, an over-the-counter immune supplement that targets pathogenic bacteria and th...

October 13, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch